DPP4 and type 2 diabetes mellitus: In patients with both T2D and chronic HCV infection, the use of dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), a class of oral antidiabetic drugs, was associated with a lower risk of HCC (43).